Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 22.47 2.42% 0.53
AKCA closed up 2.42 percent on Thursday, September 19, 2019, on 64 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical AKCA trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Weak + Overbought Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish 2.42%
NR7 Range Contraction 2.42%
NR7-2 Range Contraction 2.42%
Weak + Overbought Other 2.42%
Weak, Overbought and Reversal Signs Reversal 2.42%
Overbought Stochastic Strength 2.42%

Older signals for AKCA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Biopharmaceutical Medical Specialties Cardiology Dyslipidemia Low Density Lipoprotein Lipids Lipoproteins Antisense RNA Lipid Disorders Lipoprotein Lipase Deficiency Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.73
52 Week Low 18.68
Average Volume 174,789
200-Day Moving Average 25.7364
50-Day Moving Average 21.582
20-Day Moving Average 21.0195
10-Day Moving Average 21.388
Average True Range 1.2302
ADX 9.7
+DI 21.8572
-DI 20.6885
Chandelier Exit (Long, 3 ATRs ) 19.0094
Chandelier Exit (Short, 3 ATRs ) 22.3706
Upper Bollinger Band 22.8249
Lower Bollinger Band 19.2141
Percent B (%b) 0.9
BandWidth 17.178334
MACD Line 0.1593
MACD Signal Line -0.0879
MACD Histogram 0.2472
Fundamentals Value
Market Cap 1.44 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -11.89
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.41
Resistance 3 (R3) 24.22 23.37 24.09
Resistance 2 (R2) 23.37 22.88 23.47 23.98
Resistance 1 (R1) 22.92 22.57 23.15 23.12 23.87
Pivot Point 22.08 22.08 22.19 22.17 22.08
Support 1 (S1) 21.63 21.58 21.85 21.82 21.07
Support 2 (S2) 20.78 21.27 20.88 20.96
Support 3 (S3) 20.33 20.78 20.85
Support 4 (S4) 20.53